SS Innovations International (NASDAQ: SSII) Reports Record Q2 Revenue of $13.9M, Up 39.4%

SS Innovations International (NASDAQ: SSII) reported record second-quarter 2026 revenue of $13.9 million, up 39.4% from $10 million a year earlier, as installations of its SSi Mantra surgical robotic system increased 30.4% to 30. Gross profit rose 20% to $7.1 million, with gross margin of 50.9%, while net loss was $2.7 million, or $0.01 per diluted share, compared with a net loss of $0.3 million a year earlier. First-half revenue increased 65.6% to $25 million, while SSi Mantra installations rose 47.4% to 56. As of June 30, SS Innovations had $13.6 million in cash and cash equivalents, no long-term debt and a cumulative installed base of 224 SSi Mantra systems across 12 countries.

At a glance

Company: SS Innovations International, Inc.
Ticker: NASDAQ: SSII
Announcement: Earnings

Key figures

Second-quarter 2026 revenue: $13.9 million
Second-quarter revenue increase: 39.4%
Second-quarter net loss: $2.7 million
First-half 2026 revenue: $25 million
Cash and cash equivalents as of June 30: $13.6 million
Cumulative installed base as of June 30: 224

Products and programs

SSi Mantra surgical robotic system
SSi Mudra surgical instruments

The company reported 12,272 cumulative procedures using the SSi Mantra as of June 30, including 175 telesurgeries, and subsequently completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India. SS Innovations expects the U.S. Food and Drug Administration to complete its review of the company’s 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027 and said it believes it can obtain European Union CE marking certification by the end of 2026.

To view the full press release, visit https://ibn.fm/nTMso

About SS Innovations

SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

SS Innovations International reported second-quarter 2026 revenue of $13.9 million, a 39.4% increase from the year-earlier period. The company attributed the growth in part to higher SSi Mantra system installations, which reached 30 for the quarter. Gross profit increased, while the company recorded a net loss of $2.7 million. First-half revenue rose 65.6% to $25 million, and the company reported 56 system installations during that period. As of June 30, it had cash and cash equivalents of $13.6 million and 224 installed SSi Mantra systems across 12 countries. The company also reported 12,272 cumulative procedures and said it later completed a telesurgery between Colombia and India. SS Innovations expects FDA review of its 510(k) submission to conclude by the end of the first quarter of 2027 and believes it can obtain EU CE marking by the end of 2026.

Key takeaways

Second-quarter revenue reached $13.9 million, up 39.4% year over year.
SSi Mantra installations rose to 30 for the quarter and 56 for the first half.
The company reported a second-quarter net loss of $2.7 million.
As of June 30, the installed base totaled 224 systems across 12 countries.
The company outlined expected timelines for FDA review and EU CE marking.

SEC filings

Earlier from SS Innovations

Back to News Center